rhNGF
Ophthalmic Solution

▼ This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at www.tga.gov.au/reporting-problems.

AUSTRALIAN PRODUCT INFORMATION – OXERVATE (CENEGERMIN) EYE DROPS SOLUTION

1 NAME OF THE MEDICINE
Cenegermin

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One ml of solution contains 20 micrograms of cenegermin*.

* Recombinant form of human nerve growth factor (rhNGF) produced in Escherichia Coli.

For the full list of excipients, see Section 6.1 List of excipients.

3 PHARMACEUTICAL FORM
Eye drops solution (eye drops).

Clear, colourless solution. pH 7.0-7.4 and osmolarity 280-320 mOsm/kg

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS
Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.

4.2 DOSE AND METHOD OF ADMINISTRATION
Treatment should be initiated under the supervision of an ophthalmologist or a healthcare professional qualified in ophthalmology. Patients must be educated on how to use OXERVATE with the associated delivery system for self-administration.

The drop volume is 39 µL and each drop contains 0.78 µg of cenegermin.

Adults:
The recommended dose is one drop of OXERVATE in the conjunctival sac of the affected eye(s), 6 times a day at 2 hourly intervals, starting from the morning and within 12 hours. Treatment should be continued for eight weeks.

Patients with an eye infection should be treated before starting therapy with OXERVATE (see Section 4.4 Special warnings and precautions for use).
rhNGF
Ophthalmic Solution

If a dose is missed, treatment should be continued as normal, at the next scheduled administration. The missed dose can be administered immediately if within the 12 hours shelf life of the vial. Patients should be advised not to instil more than one drop in the affected eye(s) during any administration.

Special populations

Elderly:

No dose adjustment is required in patients 65 years of age and older.

Hepatic and renal impairment:

The medicinal product has not been studied in patients with hepatic or renal impairment. However, no dose adjustment is considered necessary in these populations.

Paediatric population:

The safety and efficacy of this medicinal product in children and adolescents below the age of 18 years have not been established. No data are available.

Method of administration

For ocular use only.

Refer to Section 6.6 Special Precautions for disposal and other handling for instructions on the preparation and handling of the medicinal product.

Precautions to be taken before administering the medicinal product:

Patients should be instructed to wash their hands before use.

OXERVATE should only be administered using the associated delivery system (vial adapter and pipettes), according to the instructions presented in Section 6.6 Special precautions for disposal and other handling. An individual pipette should be used per application.

If more than one topical ophthalmic product is being used, the eye drops must be administered at least 15 minutes apart, to avoid diluting the other product. If eye ointment, gel or other viscous eye drops are used, they should be administered 15 minutes following OXERVATE treatment (see also Section 4.5 Interactions with other medicines and other forms of interactions).

In case of concomitant use with contact lenses, see Section 4.4 Special warnings and precautions for use.

For instructions on preparation and handling of the medicinal product before administration, see Section 6.6 Special precautions for disposal and other handling.

4.3 CONTRAINDICATIONS

Hypersensitivity to the active substance or to any of the excipients listed in Section 6.1 List of excipients.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Risk of corneal melting or impending perforation

It is important that the risk of corneal melting or impending perforation, and the need to undergo emergency surgery or another procedure is assessed before starting therapy with OXERVATE as cengegermin should not be used in patients requiring immediate surgery.

Eye Reactions

OXERVATE may cause mild to moderate eye discomfort, such as eye pain, to the patient. The patient should be advised to contact the doctor in case of concern or a more severe eye reaction.

Use of corticosteroids or eye drops containing preservatives

Use of ophthalmic topical agents known to inhibit epithelial healing, including corticosteroids or eye drops containing preservatives such as benzalkonium chloride, polyquaternium-1, benzododecinium bromide, cetrimide and other quaternary ammonium derivatives, should be avoided during treatment of neurotrophic keratitis, as they could interfere with corneal healing (see Section 4.5 Interactions with other medicines and other forms of interactions).

Eye infections

An eye infection should be treated before use of OXERVATE. Should an eye infection occur, OXERVATE should be suspended until infection resolution (see Section 4.2 Dose and method of administration).

Ocular cancer

Cengegermin may theoretically affect ocular cancer, as it is a growth factor. OXERVATE should be used with caution in patients with ocular cancer. It is recommended that these patients continue to be monitored for cancer progression during and after treatment with this medicinal product.

Contact lenses

In the clinical trials of OXERVATE, patients with contact lenses were excluded. Use with contact lenses is not recommended due to concerns that removal of the lenses may impair the healing of the cornea. If the treating physician believes a patient should continue to use contact lenses, patients should be instructed to remove contact lenses before applying OXERVATE and to wait 15 minutes after instillation of the dose before reinsertion, because the presence of a contact lens (either therapeutic or corrective) could theoretically limit the distribution of cengegermin onto the area of the corneal lesion.

Use in the elderly

There are no specific concerns for use in the elderly.

Paediatric use

No data are available (see Section 4.2 Dose and method of administration).

Effects on laboratory tests

No data available.
rhNGF
Ophthalmic Solution

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Other topical ophthalmic products may be used during treatment with OXERVATE when used 15 minutes apart, with the exception of agents known to inhibit epithelial healing (e.g. corticosteroids or eye drops containing preservatives such as benzalkonium chloride, polyquaternium-1, benzoalkohol, cetrimide and other quaternary ammonium derivatives) (see Sections 4.2 Dose and method of administration and 4.4 Special warnings and precautions for use). If eye ointment, gel or other viscous eye drops are used, OXERVATE should be administered first.

No interaction studies with other medicinal products have been performed.

As systemic absorption of cenegermin after use of the medicinal product is negligible or not detectable, no drug interactions are anticipated.

4.6 FERTILITY, PREGNANCY AND LACTATION

Effects on fertility

There are no data on the effects of cenegermin on human fertility. In a rat combined fertility and early embryonic development study, daily subcutaneous doses of cenegermin of up to 160 µg/kg/day (855 times the MRHD) for at least 14 days prior to mating did not adversely affect male and female fertility.

Use in pregnancy – Pregnancy Category B3

There are no data from the use of cenegermin in pregnant women.

In an embryofetal development study, daily subcutaneous administration of cenegermin to pregnant rats throughout the period of organogenesis produced a slight increase in post-implantation loss at doses greater than or equal to 80 µg/kg/day (427 times the MRHD). A no observed adverse effect level (NOAEL) was not established for this effect. Developmental abnormalities (hydrocephaly, fused zygomatic arch, convoluted ureter) were observed at 160 µg/kg/day (855 times the MRHD) but not at 80 µg/kg/day.

As systemic exposure to cenegermin is negligible with ocular administration, the adverse fetal effects are unlikely to be clinically relevant. As a precautionary measure, it is preferable to avoid the use of OXERVATE during pregnancy.

Use in lactation

It is not known whether cenegermin is excreted in human milk.

A risk to the suckling child cannot be excluded.

A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from this therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES
4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Summary of the safety profile
The most commonly reported adverse reactions in patients suffering from neurotrophic keratitis and treated with OXERVATE during clinical studies include eye pain (11.1 %), eye inflammation (8.3 %), which may include anterior chamber inflammation and hyphaema; lacrimation increased (5.6 %), with symptoms such as eye discharge; eyelid pain (5.6 %) and foreign body sensation in the eye (5.6 %).

Eye pain was the most frequently reported adverse reaction, followed by eye irritation and abnormal sensation in the eye, when considering the whole population treated with the medicinal product (i.e. population included in clinical trials also on indications other than neurotrophic keratitis).

Table of adverse events
A summary of adverse events (
The following adverse reactions listed below were observed in clinical studies in patients suffering from neurotrophic keratitis, treated with OXERVATE 20 microgram/ml.

Adverse drug reactions are presented below according to MedDRA system organ classification (SOC and Preferred Term Level). They are ranked according to system organ class and classified according to the following convention:

- <1/1,000), very rare (<1/10,000), or not known (cannot be estimated from the available data).

Table 2: Adverse drug reactions observed in clinical studies in patients suffering from neurotrophic keratitis treated with OXERVATE

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Frequency</th>
<th>Adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections and infestations</td>
<td>Uncommon</td>
<td>Corneal abscess</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>Common</td>
<td>Headache</td>
</tr>
<tr>
<td>Eye disorders</td>
<td>Very common</td>
<td>Eye pain</td>
</tr>
</tbody>
</table>
rhNGF
Ophthalmic Solution

<table>
<thead>
<tr>
<th>Common</th>
<th>Eye inflammation, eyelid pain, foreign body sensation in the eye, lacrimation increased, blepharitis, conjunctival hyperaemia, photophobia, eye irritation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon</td>
<td>Corneal neovascularization</td>
</tr>
</tbody>
</table>

**Reporting suspected adverse effects**


**4.9 OVERDOSE**

A topical overdose is not likely to occur or to be associated with toxicity. A topical overdose of cenegermin may be flushed from the eye(s) with lukewarm water.

For information on the management of overdose, contact the Poisons Information Centre on 13 11 26 (Australia).

**5 PHARMACOLOGICAL PROPERTIES**

**5.1 PHARMACODYNAMIC PROPERTIES**

**Mechanism of action**

OXERVATE contains cenegermin, a recombinant form of human nerve growth factor. Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (i.e., TrkA) and low-affinity (i.e. p75NTR) nerve growth factor receptors located on the anterior surface of the eye. The treatment with cenegermin, administered as eye drops, is intended to allow restoration of corneal integrity.

**Clinical trials**

The efficacy and safety of OXERVATE were evaluated in two multicentre, randomised, double-masked, vehicle-controlled clinical studies (NGF0212 and NGF0214) in patients with moderate (persisted epithelial defect) or severe (corneal ulcer) neurotropic keratitis refractory to non-surgical treatments. In both studies patients received OXERVATE or vehicle 6 times daily in the affected eye(s) for 8 weeks, and underwent a follow-up period.

Study NGF0214 enrolled 48 patients (mean age 65±14 years, range 33-94 years) treated with OXERVATE 20 microgram/ml or vehicle (24 patients per arm). Study NGF0212 enrolled a total of 174 patients (mean age 61±16 years, range 18-95 years), who have been exposed to OXERVATE and vehicle without the L-methionine excipient; 156 patients were assessed independently for efficacy, comparing two different dosages of the medicinal product with 20 and 10 µg/ml cenegermin to vehicle (52 patients per arm).
rhNGF
Ophthalmic Solution  

The table below summarizes the results for complete corneal healing of the persistent epithelial defect or corneal ulcer after 8 weeks of treatment for patients who received OXERVATE 20 microgram/ml or vehicle in the two studies. The table includes the results reported on the primary endpoint, defined by both EMA and FDA.

Table 3: Results of complete corneal healing for patients who received OXERVATE using different definitions of complete healing

<table>
<thead>
<tr>
<th>Study</th>
<th>EMA definition of complete healing at Week 8¹</th>
<th>FDA definition of complete healing at Week 8²</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Study NGF0212</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rhNGF (20µg/mL)</td>
<td>37/52</td>
<td>74.0</td>
</tr>
<tr>
<td>Vehicle</td>
<td>22/52</td>
<td>43.1</td>
</tr>
<tr>
<td>Study NGF0214</td>
<td></td>
<td></td>
</tr>
<tr>
<td>rhNGF (20µg/mL)</td>
<td>15/24</td>
<td>83.3</td>
</tr>
<tr>
<td>Vehicle</td>
<td>6/24</td>
<td>42.9</td>
</tr>
</tbody>
</table>

¹ Greatest diameter of corneal fluorescein staining <0.5 mm

² Completely staining free, i.e. no residual fluorescein staining in the area of the corneal lesion at the moment of assessment. No persistent staining (i.e. not changing in shape and/ or location at different time points) elsewhere in the cornea as seen in pictures taken at different time points during the study.

The percentage of patients experiencing complete corneal clearing (grade 0 on the modified Oxford scale), the least squares mean change in best corrected distance visual acuity score (Early Treatment Diabetic Retinopathy Study letters) from baseline and any improvement in corneal sensitivity as measured in millimetres by Cochet-Bonnet aesthesiometry (difference compared to baseline >0) was also measured after 8 weeks of treatment in both studies, and summarized in the table below.

Table 4: Secondary outcomes after 8 weeks of treatment

<table>
<thead>
<tr>
<th>Results after 8 weeks of treatment: % patients</th>
<th>Study NGF0214</th>
<th>Study NGF0212</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete corneal clearing</td>
<td>OXERVATE</td>
<td>22.7 %</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
<td>4.2 %</td>
</tr>
<tr>
<td>Mean change in best corrected distance visual acuity</td>
<td>OXERVATE</td>
<td>6.11 %</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
<td>3.53 %</td>
</tr>
<tr>
<td>Improvement corneal sensitivity* inside lesion</td>
<td>OXERVATE</td>
<td>72.2 %</td>
</tr>
<tr>
<td>* using the Cochet-Bonnet aesthesiometer</td>
<td>Vehicle</td>
<td>60.0 %</td>
</tr>
</tbody>
</table>
rhNGF
Ophthalmic Solution

The following parameters were measured at Week 8 in Studies NGF0214 and NGF0212; complete corneal clearing, best corrected distance visual acuity and corneal sensitivity inside lesions. None of the measured parameters were significantly different to patients taking OXERVATE versus patients taking Vehicle, however it should be noted that the studies were not powered to detect a difference. Nevertheless, patients receiving OXERVATE generally had better trends of improvement for most efficacy endpoints versus patients receiving Vehicle.

Patients considered completely healed at the end of 8 weeks of treatment with OXERVATE did not tend to have recurrences within the 12 months follow-up period of study NGF0212. Specifically, more than 80% of the 31 patients who were healed after initial OXERVATE 20 microgram/ml treatment and for whom a response was available, remained completely healed at the end of the 12 months follow up period.

5.2 PHARMACOKINETIC PROPERTIES

Absorption
Cenegermin is mostly removed from the eye with the tear production and through the naso-lacrimal duct; the minor portion that is absorbed occurs mostly in the conjunctiva and peri-orbital tissue and to a minor extent through the cornea following ocular administration.

Pharmacokinetic profiling of patients included in studies found no accumulation effect of cenegermin. In general, the systemic absorption of OXERVATE is negligible.

Distribution
After eye drop administration, cenegermin is distributed particularly in the anterior portion of the eye, although a study with radiolabelled cenegermin in rats has shown that it also reaches the retina and other posterior parts of the eye at doses significantly higher than those administered by eye drops in humans to treat neurotrophic keratitis. At the ocular doses, cenegermin is not distributed throughout body tissues as there is no systemic absorption above the natural baseline levels.

Metabolism
No studies have been conducted.

As a protein, rhNGF is metabolised by standard proteolytic pathways with its constituent amino acids being added to the general body pool.

Excretion
No studies have been conducted.

Cenegermin administered by eye drops is mostly eliminated with the tear secretion and the remainder mostly biotransformed by local tissue proteases.

5.3 PRECLINICAL SAFETY DATA
rhNGF
Ophthalmic Solution

Genotoxicity
Genotoxicity studies were not performed as rhNGF is a biological product, which does not cross the nuclear membrane to react with DNA.

Carcinogenicity
Carcinogenicity studies were not performed as rhNGF is a biological product. Although rhNGF/cenegermin is a recombinant version of a human growth factor with a theoretical risk of carcinogenicity, negligible systemic exposures observed in patients indicate that this risk is negligible.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS
Trehalose dihydrate
Mannitol
Dibasic sodium phosphate
Monobasic sodium phosphate dihydrate
Hypromellose
Macrogol 6000
Methionine
Water for injections
Hydrochloric acid
Sodium hydroxide
Nitrogen

6.2 INCOMPATIBILITIES
Not applicable.

6.3 SHELF LIFE

Unopened vial
Stable for 2 years when stored at -20 °C.
Stable for up to 14 days when stored at 2-8°C.

Opened vial
Once opened, the product must be stored below 25 °C and used within 12 hours at 25 °C.
rhNGF
Ophthalmic Solution

From a microbiological point of view, the method of opening (i.e. by connecting the vial adapter to the vial) precludes the risk of microbial contamination.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Pharmacy
The weekly carton containing the vials must be stored in a freezer (-20 °C ±5 °C).

Patient
The patient will receive a weekly carton including 7 vials of OXERVATE in an insulated pack. As soon as the patient is at home (and no later than 5 hours from when the patient receives the product at the pharmacy), the weekly carton should be placed into the refrigerator (2-8°C). It should be noted that the frozen medicinal product received from the pharmacy could need up to 30 minutes for thawing.

An individual multi-dose vial of OXERVATE is to be removed from the fridge for use over the course of a single day. Each opened vial can be stored in the fridge or below 25 °C, but must be used within 12 hours.

After this period of time the vial contents should be discarded irrespective of whether some residual product remains in the vial.

6.5 NATURE AND CONTENTS OF CONTAINER

1 ml OXERVATE solution in sterile, preservative-free multi-dose Type I glass vials, closed with a rubber stopper and an aluminium overseal with a polypropylene flip-off cap, presented in cardboard cartons.

Pack size: Seven (7) multi-dose vials per carton

The patient will receive a weekly carton containing 7 vials of OXERVATE.

This medicinal product should only be used with specific vial adapters and disposable devices (pipettes) that will be provided separately from the weekly OXERVATE carton.

7 vial adapters (i.e. 1 per day), 42 pipettes (i.e. 6 per day) and 42 disinfectant wipes (i.e. 6 per day) sufficient to administer the medicinal product for one week will be provided separately, together with a dose recording card. Extra adapter (1), pipettes (3) and wipes (3) will also be provided as spares.
6.6 SPECIAL PRECAUTIONS FOR DISPOSAL AND OTHER HANDLING

The patient will receive a weekly carton containing 7 multi-dose vials of OXERVATE, which should be stored in a refrigerator until the day of use.

The patient will also receive separately vial adapters, pipettes and disinfectant wipes.

An individual multi-dose vial of OXERVATE should be taken from the refrigerator at the same time each morning bearing in mind the 12 hour treatment schedule. The multi-dose vial containing the product should be prepared according to the following instructions:

1) With clean freshly-washed hands, place the vial on a steady flat surface and remove the plastic flip-off cap.
2) Peel-off the back of the vial adapter blister pack.

3) Without removing the vial adapter from its blister pack, connect the vial adapter to the vial by firmly pushing the vial adapter down vertically until it snaps into place over the neck of the vial and the spike of the vial adapter pierces through the vial’s rubber stopper. *Once the vial adapter has been connected correctly, it should not be removed from the vial.*

4) Remove and discard the vial adapter blister pack. Avoid touching the surface of the adapter.
To withdraw and administer each dose of OXERVATE solution, the steps below should be followed:

5) Take an individual disinfectant wipe and gently clean the surface of the valve on the luer lock connector of the vial adapter. After cleaning, the valve should be allowed to dry for approximately one minute.

6) Take a pipette and remove it from the protective packaging.

7) Screw the pipette clockwise into the luer lock connector of the vial adapter.

8) Ensure that the pipette plunger is pushed all the way down.
9) Turn the vial upside-down with the pipette connected and gently pull the pipette plunger outwards until it stops, to draw the solution into the pipette (ensure that the plunger has reached the stop point).

10) Check the pipette and confirm that it contains some of the solution. Air bubbles may cause blockage and prevent the pipette from filling properly (especially at first withdrawal). If the pipette is empty, keep the vial with the connected pipette upside-down, push the plunger all the way in and pull it out again.

11) Once it has been correctly filled, unscrew the pipette from the luer lock connector of the vial adapter.
rhNGF
Ophthalmic Solution

Product Information
rhNGF
Ophthalmic Solution

12) Hold the pipette, pointing down, between the middle finger and thumb, tilt the head back and position the pipette above the affected eye. Pull down the lower eyelid. Gently push the pipette plunger in until a single drop is instilled into the conjunctival fornix.

13) Immediately discard the used pipette and wipe after instillation.

14) If a mistake is made and a drop is not instilled into the eye, repeat the steps described above using a new pipette and wipe.

15) Throughout the day, the vial can either be placed back in the fridge after each use or stored below 25 °C (with the vial adapter still connected).

The administration instructions above (steps 5 to 15) should be repeated every 2 hours (six times per day) using a new disinfectant wipe and a new pipette each time.

The vial and any remaining solution must be discarded at the end of the day, and no later than 12 hours from the time the vial adapter was connected (irrespective of whether any residual solution remains in the vial).
To ensure accurate dosing every 2 hours, the patient should be advised to set an alarm as a reminder for dosing.

To control that six doses have been taken every day, the patient should be advised to use the weekly dose recording card provided with the delivery system. On that card the patient should track the date of the first use of the weekly supply, the time of the vial opening (i.e. when the vial adapter is connected to the vial), and the time of daily ocular instillations occurring over the week.

A new OXERVATE supply will be issued each week for the duration of the treatment period.

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

### 6.7 PHYSICOCHEMICAL PROPERTIES

#### Chemical structure

The amino acid sequence of mature rhNGF with the mapping of disulphide bridges (Cys\textsubscript{15}-Cys\textsubscript{80}, Cys\textsubscript{58}-Cys\textsubscript{108} and Cys\textsubscript{68}-Cys\textsubscript{110}):

```
SSSHPIFHRGEFSVQDSVSZWVCDKTTATIDIKGEVMVLCEVNINNSVFKQYF
38
PETKCRDDNVDSDGCRGIDSKHWSYCTTTHTFVKALTMDCKQAAWFIRIDT
68
ACVCVLSRKAVR
80

Cys\textsubscript{108} Cys\textsubscript{110}
```

#### CAS number

1772578-74-1

### 7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription only medicine - S4

### 8 SPONSOR

JACE Pharma Pty Ltd

Level 1, 7 Clunies-Ross Court

Brisbane Technology Park

Eight Mile Plains, Queensland, 4113

Australia.

### 9 DATE OF FIRST APPROVAL

01 October 2019
rhNGF
Ophthalmic Solution

10 DATE OF REVISION

SUMMARY TABLE OF CHANGES

<table>
<thead>
<tr>
<th>Section Changed</th>
<th>Summary of new information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>